Cadrenal Therapeutics, Inc.

During the three months ended September 30, 2025, no officer or director of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “nonRule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, other than as set forth below.

On September 23, 2025, Quang X. Pham, the Chief Executive Officer of the Company, entered into a written stock selling plan in accordance with Rule 10b5-1 of the Exchange Act and the Company’s Insider Trading Policy, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (the “ Pham 10b5-1 Plan”). The Pham 10b5-1 Plan allows for the sale of a maximum of 154,571 shares of our common stock (less such number of shares of common stock that are sold pursuant to the written stock selling plan in accordance with Rule 10b5-1 that was entered into by Mr. Pham on May 9, 2025, subsequent to September 23, 2025 until the date such prior plan terminates), over an approximate nine month period subject to the terms and conditions of the Pham 10b5-1 Plan, including specified minimum price and volume parameters. The term of the Pham 10b5-1 Plan begins on December 23, 2025 and terminates on September 30, 2026.

On September 18, 2025, Matthew Szot, the Chief Financial Officer of the Company, entered into a written stock selling plan in accordance with Rule 10b5-1 of the Exchange Act and the Company’s Insider Trading Policy, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (the “Szot 10b5-1 Plan”). The maximum number of shares available to be sold under the Szot 10b5-1 Plan will be equal to 100% of all unsold shares (not to exceed 9,933 shares) of common stock from the written stock selling plan entered into by Mr. Szot on May 9, 2025 (the “Prior Szot 10b5-1 Plan”) on the date when such Prior Szot 10b5-1 Plan terminates, over an approximate six and one-half month period subject to the terms and conditions of the Szot 10b5-1 Plan, including specified minimum price and volume parameters, in accordance with Rule 10b5-1. The term of the Szot 10b5-1 Plan begins on December 18, 2025 and terminates on June 30, 2026.